AstraZeneca PLC (AZN)vsNutex Health Inc (NUTX)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
NUTX
Nutex Health Inc
$200.24
+2.58%
HEALTHCARE · Cap: $1.32B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 7147% more annual revenue ($61.37B vs $846.72M). NUTX leads profitability with a 21.2% profit margin vs 17.0%. NUTX trades at a lower P/E of 7.5x. NUTX earns a higher WallStSmart Score of 63/100 (C+).
AZN
Buy60
out of 100
Grade: C+
NUTX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+61.7%
Fair Value
$269.07
Current Price
$200.24
$68.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Attractively priced relative to earnings
Strong operational efficiency at 57.8%
Earnings expanding 95.9% YoY
Every $100 of equity generates 28 in profit
Keeps 21 of every $100 in revenue as profit
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Revenue declined 13.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : NUTX
The strongest argument for NUTX centers on P/E Ratio, Operating Margin, EPS Growth. Profitability is solid with margins at 21.2% and operating margin at 57.8%.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : NUTX
The primary concerns for NUTX are Market Cap, Revenue Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while NUTX is a declining play — different risk/reward profiles.
NUTX carries more volatility with a beta of 2.02 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
NUTX scores higher overall (63/100 vs 60/100), backed by strong 21.2% margins. AZN offers better value entry with a 18.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Nutex Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?